We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The old adage “better late than never” may seem tired, but it could be apropos for Pfizer’s newly FDA-approved PARP inhibitor, Talzenna. Pfizer picked up the drug in its $14 billion acquisition of Medivation in 2017, when it ...